Skip to main content

Advertisement

SpringerLink
Log in

Cancer immunology

CD8+ T cell killing of MHC class I–deficient tumors

  • News & Views
  • Published:

From Nature Cancer

View current issue Submit your manuscript

CD8+ T cells recognize tumor-associated antigens presented by major histocompatibility complex (MHC) class I molecules. How CD8+ T cells eliminate cancer cells deficient in MHC class I has been unclear. A study now shows that adaptive CD8+ T cell activation induces expression of the innate receptor NKG2D for the elimination of MHC class I–deficient tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: Adaptive immunity primes CD8+ T cells to kill MHC class I–deficient tumors via the induced expression of innate receptor NKG2D.

References

  1. Zaretsky, J. M. et al. N. Engl. J. Med. 375, 819–829 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Busch, E. et al. Front. Oncol. 11, 669774 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Middha, S. et al. JCO Precis. Oncol. 3, PO.18.00321 (2019).

    PubMed  PubMed Central  Google Scholar 

  4. Zhang, H. et al. Sci. Rep. 11, 5045 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Tang, F. et al. CNS Neurosci. Ther. 27, 951–962 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lerner, E. C. et al. Nat. Cancer https://doi.org/10.1038/s43018-023-00600-4 (2023).

    Article  PubMed  Google Scholar 

  7. Lanier, L. L. Annu. Rev. Immunol. 23, 225–274 (2005).

    Article  CAS  PubMed  Google Scholar 

  8. Rudd, C. E. & Schneider, H. Nat. Rev. Immunol. 3, 544–556 (2003).

    Article  CAS  PubMed  Google Scholar 

  9. Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W. & Jung, H. Annu. Rev. Immunol. 31, 413–441 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sentman, C. L. & Meehan, K. R. Cancer J. 20, 156–159 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. de Vries, N. L. et al. Nature 613, 743–750 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  12. Liu, G. et al. J. Clin. Invest. 123, 4410–4422 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chu, T. et al. Cell Rep. 3, 701–808 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Upadhyay, R. et al. Cancer Discov. 11, 599–613 (2021).

    Article  CAS  PubMed  Google Scholar 

  15. Rudd, C. E. Front. Cell Dev. https://doi.org/10.3389/fcell.2021.626095 (2021).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Université de Montréal, Montreal, Quebec, Canada

    Christopher E. Rudd

  2. Division of Endocrinology and Metabolism, Department of Medicine & Health Sciences, McGill University, Montreal, Quebec, Canada

    Christopher E. Rudd

  3. Division of Immunology Oncology, Centre de Recherche–Hôpital Maisonneuve-Rosemont (CR-HMR), Montreal, Quebec, Canada

    Christopher E. Rudd

Authors
  1. Christopher E. Rudd
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher E. Rudd.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rudd, C.E. CD8+ T cell killing of MHC class I–deficient tumors. Nat Cancer 4, 1214–1216 (2023). https://doi.org/10.1038/s43018-023-00606-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00606-y

  • Springer Nature America, Inc.

Search

Navigation